IL6 and chronic obstructive pulmonary disease: It has been reported that chronic obstructive pulmonary disease (COPD) patients have high levels of IL-6 and nitric oxide (NO), and GTS-21 treatment suppresses the IL-6 and NO levels in plasma by modulating the function of PBMCs (351).